Houston, TX (PRWEB) December 21, 2013
68Ge/68Ga generator allows for on-site production of positron emitter, 68GaCl3 and on-demand labeling of chelator-based tracers. There is growing interest in development and clinical translation of new 68Ga –radiopharmaceuticals. Number of the clinical trials of 68Ga-radiotracers has been increasing in the last few years. The collaborative agreement between RadioMedix Inc. and ITG GmbH will improve access to 68Ga technology and make it more affordable.
“This is a significant advance in our collaboration that will have a great impact on the research community and clinicians working in the area of 68Ga-agents”, said Dr. Ebrahim S. Delpassand, CEO and Chairman of RadioMedix. “As a physician and the Principal Investigator on the clinical trial of 68Ga-DOTATATE, I have noticed the impact this tracer made on the early and accurate diagnosis of NET patients and evaluation of their response to therapy”. “We have been working with ITG GmbH 68Ge/68Ge generators for the past 3 years”, said Dr. Izabela Tworowska, CSO of RadioMedix. “ITG GmbH generators provide competitive advantages over other commercially available generators delivering stable elution profile, limiting the 68Ge breakthrough and metal contamination. Their use has significantly simplified the labeling protocol of our clinical doses of Ga-68 DOTATATE.”
“New design of our 68Ge/68Ge generator and the use of the organic matrix for germanium immobilization help us overcome limitation observed in loading of 68Ge on the metallic support”, “The US market provides unique opportunities for our expansion and RadioMedix vast network and scientific expertise will help us in approaching new clients in North America”; said Dr. Sebastian Marx, (Marketing Director, ITG GmBH).
RadioMedix, Inc. is a clinical phase biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and therapy of cancer. The company is commercializing generator-produced radiopharmaceuticals based on Gallium-68 chemistry. RadioMedix is in late-stage development of a new radiolabeled analog targeting metabolic pathway, GlucoMedix™, which is based on its patented DO2A-chelation technology and SmartMedix™, the automated module for labeling and purification of tracers. RadioMedix is providing consulting services, on the design and structure optimization of agents and their pre-clinical validation. RadioMedix is also compounding and labeling of the clinical doses of radiotracers for pharmacies and clinical sites, and providing training in dose preparation and documentation for the IND applications.
The ITM GmBH is a subsidiary of the ITM Group, the leading pharmaceutical company for the development, production and worldwide distribution of next generation medical radioisotopes and fully integrated radionuclide based medical devices. Our advanced platform covers all aspects of an innovative radiopharmaceutical value chain. Both, our comprehensive product portfolio and our promising pipeline provide us with the capability to sustainably set industry standards in diagnostics and therapy.